PSK Pharma has registered Iloprost PSK for the treatment of moderate and severe pulmonary hypertension, the pharmaceutical company said. The solution for inhalation will be produced at a factory in the Dubna economic zone in the Moscow region.
“When inhaled, the drug causes an expansion of the pulmonary arterial bed, reducing pressure in the pulmonary arteries and vascular resistance, as well as increasing cardiac output and blood oxygen saturation,” the company explained the action of Iloprost PSK.
Earlier it was reported that PSK Pharma, the largest resident of the pharmaceutical cluster of the Dubna SEZ, is developing eight drugs for the treatment of asthma and chronic obstructive pulmonary disease.
It should be noted that, according to the State Register of Medicines in Russia, drugs containing the active substance iloprost are already available from Russian manufacturers Pharmasynthesis and Oda Pharma, as well as from German Bayer and Turkish GEN İlaç ve Sağlık Ürünleri.
